KR950700081A - 이중 캐리어 면역원성 구성물 - Google Patents

이중 캐리어 면역원성 구성물

Info

Publication number
KR950700081A
KR950700081A KR1019940702762A KR19940702762A KR950700081A KR 950700081 A KR950700081 A KR 950700081A KR 1019940702762 A KR1019940702762 A KR 1019940702762A KR 19940702762 A KR19940702762 A KR 19940702762A KR 950700081 A KR950700081 A KR 950700081A
Authority
KR
South Korea
Prior art keywords
carrier
immunogenic construct
dual
protein
dual carrier
Prior art date
Application number
KR1019940702762A
Other languages
English (en)
Inventor
W 로우 죤
Original Assignee
W 로우 죤
헨리 엠. 젝슨 파운데이션 포디어드벤스 먼트 오브 밀리티리메디션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by W 로우 죤, 헨리 엠. 젝슨 파운데이션 포디어드벤스 먼트 오브 밀리티리메디션 filed Critical W 로우 죤
Publication of KR950700081A publication Critical patent/KR950700081A/ko

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6068Other bacterial proteins, e.g. OMP
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087Polysaccharides; Lipopolysaccharides [LPS]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806Antigenic peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

이중 캐리어 면역원성 구성물은 최소한 하나의 70KD 이상의 고분자량 분자로 구성된 제일 캐리어와 제일 캐리어에 콘쥬게이트된 T-의존성 항체를 포함하는 최소한 하나의 제이 캐리어를 포함한다.
상기 이중 캐리어 면역원성 구성물은 합텐 또는 항원과 같은 모이어티를 더욱 포함하기도 한다. 상기 면역원성 구성물은 질병의 진단, 치료 및 예방에 사용하기에 적당하다.

Description

이중 캐리어 면역원성 구성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 필요로하는 T-세포의 종류에 기초한 두 타입의 항체의 예시도, T-독립성 항원(및 합텐화된 TI 항원)은 T 세포의 부재하에서 반응을 자극하며, T-의존성 항체( 및 합텐화된 TD 항체)는 최적의 항체반응을 유도하기 위하여 T 세포의 참여를 필요로 한다, 제2도는, 이중 캐리어 면역원성 구성물의 일실시예의 개략도; -상기 제일 캐리어는 고분자량 폴리머이며(HMWP), 예로 댁스트란(Dex)이 있다; -Dex와 콘쥬게이트된 상기 제이 캐리어는 높은 수준의 T세포의 활성화를 자극하는 어떠한 기질일 수 있다;- 상기 합텐은 제어 캐리어에 콘쥬게이트된 올리고사카라이드, 폴리사카라이드, 펩타이드, 약등과 같은 매우 낮은 분자량의 분자이다. 제3도는 BSA-Dex 콘쥬게이트에 반응하는 1회 투여량을 나타내는 그래프, 소의 혈청 알부민(BSA)에 대한 혈청 IgG1 항체의 적정량(titers)을 10--500ug/생쥐의 범위의 투여량으로 PBS 콘쥬게이트내의 BSA-Dex로 정맥내 면역된 생쥐에서 측정하였다. 면역된 후 14일 후 생쥐로부터 채혈하였고, ELISA로 항체의 적정량을 측정하였다. 콘쥬게이트 되지않은 BSA는 생쥐에서 면역원성이 아니다. 본 도면은 Dex에 콘쥬게이트되면 BSA가 매우 강력한 면역항체로 전환됨을 보여준다.

Claims (49)

  1. 분자량 70KD 이상의 고분자량 분자를 포함하는 최소한 하나의 제일 캐리어 및 제일 캐리어에 콘쥬게이트된 T-의존성 항원을 포함하는 최소한 하나의 제이 캐리어를 포함하는 이중 캐리어 면역원성 구성물.
  2. 제1항에 있어서, 상기 구성물의 면역원성이 최소한 하나의 캐리어 단독의 면역원성보다 큰 이중 캐리어 면역원성 구성물.
  3. 제1항에 있어서, 최소한 하나의 제일 캐리어의 분자량이 400kDa 이상인 이중 캐리어 면역원성 구성물.
  4. 제1항에 있어서, 최소한 하나의 제일 캐리어의 분자량이 2000kDa 이상인 이중 캐리어 면역원성 구성물.
  5. 제1항에 있어서. 최소한 하나의 제일 캐리어는 T-의존성 항원인 이중 캐리어 면역원성 구성물.
  6. 제1항에 있어서, 최소한 하나의 제일 캐리어는 댁스트란, 피콜, 폴리아크릴아미드, 마이크로비얼 폴리사카라이드, 및 그들의 조합물로 이루어진 군에서 선택되는 이중 캐리어 면역원성 구성물.
  7. 제6항에 있어서, 최소한 하나의 제일 캐리어는 댁스트란인 이중 캐리어 면역원성 구성물.
  8. 제6항에 있어서, 최소한 하나의 제일 캐리어는 피콜인 이중 캐리어 면역원성 구성물.
  9. 제6항에 있어서, 최소한 하나의 제일 캐리어는 폴리아크릴아미드인 이중 캐리어 면역원성 구성물.
  10. 제5항에 있어서, 최소한 하나의 제이 캐리어는 단백질인 이중 캐리어 면역원성 구성물.
  11. 제10항에 있어서, 상기 단백질은 바이러스 단백질, 박테리아 단백질, 기생충 단백질, 동물 단백질 및 곰팡이 단백질로 이루어진 군에서 선택되는 이중 캐리어 면역원성 구성물.
  12. 제10항에 있어서, 상기 단백질은 파상풍 톡소이드, 디프테리아 톡소이드, 페르투시스 톡소이드, 박테리아의 외막 단백질, 바이러스의 외막 단백질, 및 그들의 조합물로 이루어진 군에서 선택되는 이중 캐리어 면역원성 구성물.
  13. 제1항에 있어서. 최소한 하나의 제일 캐리어는 다수개의 제이 캐리어와 콘쥬게이트되는 이중 캐리어 면역원성 구성물.
  14. 제1항에 있어서, 어드쥬번트를 더욱 포함하는 면역원성 구성물.
  15. 최소한 하나의 제1항의 이중 캐리어 면역원성 구성물, 및 약학적으로 허용되는 캐리어를 포함하는 백신.
  16. 환자에게 제15항의 백신을 면역자극의 양으로 투여하는 환자의 치료방법.
  17. 제16항에 있어서, 상기 백신을 정맥내, 근육내, 또는 피하로 투여하는 방법.
  18. 면역항원에 대항하는 항체를 생성하기 위해 제15항의 백신으로 호스트를 면역시키고, 제공자로부터 항체 또는 B 세포를 분리하는; 공정을 포함하는 박테리아, 리케트시아, 바이러스, 기생물질, 곰팡이 또는 화학물질에 의하여 야기되는 질병에 대한 항체의 제조방법.
  19. 제18항의 방법으로 제조된 상기 항체를 포함하는 면역 요법성 조성물.
  20. 제18항에 있어서, 모노클로날 항체를 생상하기 위하여 상기 B 세포가 사용되는 면역 요법성 조성물.
  21. 제19항의 면역요법성 조성물을 치료에 효과적인 양으로 환자에게 투여하는 것을 포함하는 환자의 치료 방법.
  22. 분자량 70kDa 이상의 고분자량 분자를 포함하는 최소한 하나의 제일 캐리어, 상기 제일 캐리어와 콘쥬게이트된 T-의존성 항원을 포함하는 최소한 하나의 제이 캐리어, 및 제일 또는 제이 캐리어중 하나에 콘쥬게이트된 합텐, 항원, 및 그들의 조합물로 이루어진 군에서 선택된 최소한 하나의 모이어티를 포함하는 이중 면역원성 구성물.
  23. 제22항에 있어서, 상기 콘쥬게이트된 모이어티의 면역원성은 콘쥬게이트되지 않은 모리어티의 면역원성보다 큰 이중 캐리어 면역원성 구성물.
  24. 제22항에 있어서, 최소한 하나의 제일 캐리어의 분자량이 400kDa 이상인 이중 캐리어 면역원성 구성물.
  25. 제22항에 있어서, 최소한 하나의 제일 캐리어의 분자량이 2000kDa 이상인 이중 캐리어 면역원성 구성물.
  26. 제22항에 있어서, 최소한 하나의 제일 캐리어는 T-독립성 항원인 이중 캐리어 면역원성 구성물.
  27. 제22항에 있어서, 최소한 하나의 제일 캐리어는 댁스트란, 피콜, 폴리아크리아미드, 마이크로비얼 폴리사카라이드 및 그들의 조합물로 이루어진 군에서 선택되는 이중 캐리어 면역원성 구성물.
  28. 제27항에 있어서, 최소한 하나의 제일 캐리어는 댁스트란인 이중 캐리어 면역원성 구성물.
  29. 제27항에 있어서, 최소한 하나의 제일 캐리어는 피콜인 이중 캐리어 면역원성 구성물.
  30. 제27항에 있어서, 최소한 하나의 제일 캐리어는 폴리아크릴아미드인 이중 캐리어 면역원성 구성물.
  31. 제22항에 있어서, 최소한 하나의 제이 캐리어는 단백질인 이중 캐리어 면역원성 구성물.
  32. 제31항에 있어서, 상기 단백질은 바이러스 단백질, 박테리아 단백질, 기생충 단백질, 동물 단백질, 및 곰팡이 단백질로 이루어진 군에서 선택되는 이중 캐리어 면역원성 단백질.
  33. 제31항에 있어서, 상기 단백질은 파상풍 톡소이드, 디프테리아 톡소이드, 페르투시스 톡소이드, 박테리아의 외막 단백질, 바이러스의 외막 단백질, 및 그들의 조합물로 이루어진 군에서 선택되는 이중 캐리어 면역원성 구성물.
  34. 제22항에 있어서, 최소한 하나의 모이어티가 제일 캐리어와 커플된 이중 캐리어 면역원성 구성물.
  35. 제22항에 있어서, 최소한 하나의 모이어티가 제이 캐리어와 커플된 이중 캐리어 면역원성 구성물.
  36. 제22항에 있어서. 최소한 하나의 제일 캐리어는 다수개의 제이 캐리어와 콘쥬게이트되는 이중 캐리어 면역원성 구성물.
  37. 제22항에 있어서, 제일 캐리어에 콘쥬게이트된 최소한 하나의 제이 캐리어는 최소한 하나의 합텐과 더욱 콘쥬게이트되는 이중 캐리어 면역원성 구성물.
  38. 제22항에 있어서, 어드쥬번트를 더욱 포함하는 이중 캐리어 면역원성 구성물.
  39. 최소한 하나의 제22항의 이중 캐리어 면역원성 구성물, 및 약학적으로 허용되는 캐리어를 포함하는 백신.
  40. 제39항의 백신을 환자에게 면역자극의 양으로 투여하는 환자의 치료 방법.
  41. 제40항에 있어서, 상기 백신은 정맥내, 근육내, 또는 피하에 투여되는 방법.
  42. 면역항원에 대항하는 항체를 생성하기 위하여 제39항의 백신으로 호스트를 면역시키고, 제공자로부터 항체 또는 B 세포를 분리하는; 공정을 포함하는 박테리아, 리케트시아, 바이러스, 기생물질, 곰팡이 또는 화학물질에 의하여 야기되는 질병에 대한 항체의 제조방법.
  43. 제42항의 방법으로 제조된 항체를 포함하는 면역요법성 조성물.
  44. 제42항에 있어서, 모노클로날 항원을 생산하기 위하여 상기 B 세포를 사용하는 면역요법성 조성물.
  45. 제43항의 면역요법성 조성물을 치료에 효과적인 양으로 환자에게 투여하는 것을 포함하는 환자의 치료 방법.
  46. 제42항의 방법으로 제조된 항체를 포함하는 진단 시약.
  47. 제42항의 방법으로 제조된 항체를 포함하는 연구 시약.
  48. 제1항에 있어서, 각 캐리어의 면역원성은 다른 캐리어와 콘쥬게이트되어 향상되는 이중 캐리어 면역원성 구성물.
  49. 제22항에 있어서, 상기 각 캐리어의 면역원성은 다른 캐리어와 콘쥬게이트되어 향상되며, 상기 모이어티의 면역원성은 캐리어와 콘쥬게이트되어 향상되는 이중 캐리어 면역원성 구성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940702762A 1992-02-11 1993-02-10 이중 캐리어 면역원성 구성물 KR950700081A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83406792A 1992-02-11 1992-02-11
US07/834,067 1992-02-11
PCT/US1993/001424 WO1993015760A1 (en) 1992-02-11 1993-02-10 Dual carrier immunogenic construct

Publications (1)

Publication Number Publication Date
KR950700081A true KR950700081A (ko) 1995-01-16

Family

ID=25266015

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940702762A KR950700081A (ko) 1992-02-11 1993-02-10 이중 캐리어 면역원성 구성물

Country Status (13)

Country Link
US (2) US5585100A (ko)
EP (3) EP0911036A3 (ko)
JP (1) JP3917172B2 (ko)
KR (1) KR950700081A (ko)
AT (1) ATE245446T1 (ko)
AU (1) AU685047B2 (ko)
CA (1) CA2129899C (ko)
DE (1) DE69333107T2 (ko)
ES (1) ES2204900T3 (ko)
IL (1) IL104696A (ko)
NZ (1) NZ249704A (ko)
WO (1) WO1993015760A1 (ko)
ZA (1) ZA93945B (ko)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100376361B1 (ko) * 1993-09-22 2003-07-18 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신 면역원성구조체의제조를위하여신규한시아닐레이팅시약을사용하여용해성탄수화물을활성화하는방법
US5849301A (en) * 1993-09-22 1998-12-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
US5874085A (en) * 1993-11-10 1999-02-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Vaccine for enhanced production of IgA antibodies
WO1995032738A1 (en) * 1994-05-31 1995-12-07 Allergan, Inc. Modification of clostridial toxins for use as transport proteins
GB9410871D0 (en) 1994-05-31 1994-07-20 Imperial College Modification of tetanus toxin for use as a transport protein
DE122009000055I1 (de) * 1995-03-22 2009-12-31 Jackson H M Found Military Med Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden
ATE241384T1 (de) * 1995-03-22 2003-06-15 Jackson H M Found Military Med Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden
JPH10504842A (ja) * 1995-06-06 1998-05-12 ヘンリー エム. ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン 二重担体免疫原性構築物
CN1146444C (zh) 1995-06-23 2004-04-21 史密斯克莱·比奇曼生物公司 含有吸附于磷酸铝上的多糖偶联抗原的疫苗组合物
US6106828A (en) * 1996-02-15 2000-08-22 Novo Nordisk A/S Conjugation of polypeptides
US6309646B1 (en) 1996-05-09 2001-10-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates
US6248334B1 (en) * 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
US6299881B1 (en) * 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
ATE364395T1 (de) 1998-04-10 2007-07-15 Andrew Lees Konjugat-impfstoffe zur vorbeugung der zahnkaries
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
JP5138844B2 (ja) 1998-06-12 2013-02-06 ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド 抗原およびEBVGp350/220の受容体の同時刺激によるB細胞活性化および免疫グロブリン分泌の増強
AU767047B2 (en) * 1998-07-20 2003-10-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Vaccines against (escherichia coli) O157 infection
US6858211B1 (en) * 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
US6585973B1 (en) 1998-10-29 2003-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for preparing solid phase conjugated vaccine
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
WO2000076538A1 (en) 1999-06-10 2000-12-21 Michigan State University Feline calicivirus isolated from cat urine and vaccines thereof
US7419668B1 (en) 1999-09-02 2008-09-02 Board Of Trustees Of Michigan State University Vaccine to control equine protozoal myeloencephalitis in horses
AU7108700A (en) 1999-09-02 2001-03-26 Michigan State University Vaccine to control equine protozoal myeloencephalitis in horses
AU783144B2 (en) 2000-02-21 2005-09-29 H. Lundbeck A/S Novel method for down-regulation of amyloid
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7097837B2 (en) 2001-02-19 2006-08-29 Pharmexa A/S Synthetic vaccine agents
AU2002233166B2 (en) * 2001-02-19 2006-06-29 Pharmexa A/S Synthetic vaccines comprising polyhydroxypolymer carriers
US20030138434A1 (en) * 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
JP2006500963A (ja) 2002-08-02 2006-01-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン組成物
WO2004039417A2 (en) 2002-11-01 2004-05-13 Glaxosmithkline Biologicals S.A. Drying process
AU2004209981B2 (en) * 2003-02-01 2009-02-26 Janssen Sciences Ireland Uc Active immunization to generate antibodies to soluble A-beta
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
WO2005032584A2 (en) 2003-10-02 2005-04-14 Glaxosmithkline Biologicals S.A. Pertussis antigens and use thereof in vaccination
PT1701968E (pt) * 2003-12-17 2015-09-11 Wyeth Llc Conjugados de transportadores de péptidos imunogénicos e métodos para produzir os mesmos
TWI357414B (en) 2003-12-17 2012-02-01 Wyeth Llc Aβ immunogenic peptide carrier conjugates and meth
US20050169941A1 (en) * 2004-01-29 2005-08-04 Andrew Lees Use of amino-oxy functional groups in the preparation of protein-polysaccharide conjugate vaccines
WO2006066049A2 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
JP2008523815A (ja) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド 認知の改善における使用のためのヒト化アミロイドβ抗体
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
MX2007016403A (es) 2005-06-27 2008-03-07 Glaxosmithkline Biolog Sa Composicion inmunogenica.
WO2007012944A2 (en) * 2005-07-28 2007-02-01 Pfizer Products Inc. Methods of vaccine administration, new feline caliciviruses, and treatments for immunizing animals against feline paraovirus and feline herpes virus
AR058592A1 (es) 2005-12-22 2008-02-13 Glaxosmithkline Biolog Sa Vacuna
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EP1982176A1 (en) * 2006-01-30 2008-10-22 Dako Denmark A/S High-speed quantification of antigen specific t-cells in whole blood by flow cytometry
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
WO2008116468A2 (en) * 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
CN101883583B (zh) 2007-06-26 2017-05-17 葛兰素史密丝克莱恩生物有限公司 含有肺炎链球菌荚膜多糖缀合物的疫苗
EP2167537A2 (en) * 2007-07-03 2010-03-31 Dako Denmark A/S Compiled methods for analysing and sorting samples
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
GB0817244D0 (en) * 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US20120135037A1 (en) 2009-06-01 2012-05-31 Mizel Steven B Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
WO2011017101A2 (en) 2009-07-27 2011-02-10 Fina Biosolutions, Llc Method for producing protein-carbohydrate vaccines reduced in free carbohydrate
WO2011036560A2 (en) 2009-09-23 2011-03-31 Novartis Ag Glycoconjugate compositions and methods for treatment of hiv
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
CA2836140C (en) 2009-12-17 2016-06-21 Fina Biosolutions, Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
JP2013521770A (ja) 2010-03-10 2013-06-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン組成物
AU2010351576B2 (en) 2010-04-23 2014-08-14 FinaBioSolutions, LLC Simple method for simultaneous removal of multiple impurities from culture supernatants to ultralow levels
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
MX356426B (es) * 2011-04-04 2018-05-29 Univ Iowa Res Found Metodos para mejorar inmunogenicidad de vacuna.
GB201106225D0 (en) 2011-04-13 2011-05-25 Glaxosmithkline Biolog Sa Fermentation process
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
ES2750525T3 (es) 2012-12-27 2020-03-26 Glaxosmithkline Biologicals Sa Procedimientos y composiciones relacionados con CRM197
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
WO2015095868A1 (en) 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
AU2015208821B2 (en) 2014-01-21 2017-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
SI3583947T1 (sl) 2014-01-21 2024-01-31 Pfizer Inc. Kapsularni polisaharidi streptococcus pneumoniae in njihovi konjugati
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
PL3244917T3 (pl) 2015-01-15 2023-07-17 Pfizer Inc. Kompozycje immunogenne do zastosowania w szczepionkach przeciwko pneumokokom
TWI718144B (zh) 2015-05-04 2021-02-11 美商輝瑞股份有限公司 B型鏈球菌多醣-蛋白質軛合物、製造軛合物之方法、含軛合物之免疫原性組成物、及其用途
SI3313436T1 (sl) 2015-06-23 2021-09-30 Biological E Limited Multivalentno konjugirano pnevmokokno cepivo
KR102225282B1 (ko) 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
WO2017085586A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
EP3474890A1 (en) 2016-06-22 2019-05-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften E. V. Pneumococcal polysaccharide-protein conjugate composition
EP3269385A1 (en) 2016-07-12 2018-01-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumococcal polysaccharide-protein conjugate composition
SG11201900794PA (en) 2016-08-05 2019-02-27 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
CA3031797A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
JP2019529497A (ja) 2016-09-30 2019-10-17 バイオロジカル イー リミテッド 多糖類−タンパク質コンジュゲートを含む多価肺炎球菌ワクチン組成物
US11027005B2 (en) 2016-10-20 2021-06-08 Km Biologics Co., Ltd. Method for producing Hib conjugate vaccine using PRP with lowered molecular weight
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
HRP20220573T1 (hr) 2017-01-20 2022-06-10 Pfizer Inc. Imunogeni pripravci, namijenjeni upotrebi u pneumokoknim cjepivima
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
EP3576759A4 (en) 2017-01-31 2020-11-11 Merck Sharp & Dohme Corp. PROCESS FOR THE PREPARATION OF CAPSULE POLYSACCHARIDE PROTEIN CONJUGATES FROM STREPTOCOCCUS PNEUMONIAE SEROTYPE 19F
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
AU2018328037B2 (en) 2017-09-07 2024-03-07 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
SG11202005255PA (en) 2017-12-06 2020-07-29 Merck Sharp & Dohme Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
WO2020016322A1 (en) 2018-07-19 2020-01-23 Glaxosmithkline Biologicals Sa Processes for preparing dried polysaccharides
EP3894431A2 (en) 2018-12-12 2021-10-20 GlaxoSmithKline Biologicals SA Modified carrier proteins for o-linked glycosylation
EP3893926A1 (en) 2018-12-12 2021-10-20 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
TWI788610B (zh) 2018-12-19 2023-01-01 美商默沙東有限責任公司 包含肺炎鏈球菌多醣-蛋白質結合物之組合物及其使用方法
US20220118072A1 (en) 2019-02-11 2022-04-21 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP3757217A1 (en) 2019-06-27 2020-12-30 GlaxoSmithKline Biologicals S.A. Methods for protein purification
CA3148824A1 (en) 2019-07-31 2021-02-04 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
CN115605222A (zh) 2019-09-27 2023-01-13 辉瑞公司(Us) 脑膜炎奈瑟氏菌组合物及其方法
CN115362177A (zh) 2020-02-21 2022-11-18 辉瑞公司 糖类的纯化
EP3900739A1 (en) 2020-04-21 2021-10-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein
EP3919076A1 (en) 2020-06-02 2021-12-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic oligosaccharide vaccines against streptococcus pneumoniae with microparticle adjuvant formulations
JP2023529925A (ja) 2020-06-12 2023-07-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ナノ粒子ワクチンを使用する細菌免疫化
BR112022023234A2 (pt) 2020-06-25 2023-01-03 Glaxosmithkline Biologicals Sa Proteínas de exotoxina a modificada
EP4203995A1 (en) 2020-08-26 2023-07-05 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
EP4213870A1 (en) 2020-09-17 2023-07-26 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof
EP4232593A1 (en) 2020-10-22 2023-08-30 Pfizer Inc. Methods for purifying bacterial polysaccharides
AU2021373358A1 (en) 2020-11-04 2023-06-01 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
WO2023111826A1 (en) 2021-12-14 2023-06-22 Glaxosmithkline Biologicals Sa Bacterial immunization using qbeta hairpin nanoparticle constructs
WO2023118033A1 (en) 2021-12-22 2023-06-29 Glaxosmithkline Biologicals Sa Vaccine
US20240181028A1 (en) 2022-11-22 2024-06-06 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4169137A (en) * 1974-12-20 1979-09-25 Block Engineering, Inc. Antigen detecting reagents
US4415552A (en) * 1979-02-06 1983-11-15 The Governors Of The University Of Alberta Composition for establishing immunological tolerance
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
DE3224788A1 (de) * 1981-07-17 1983-02-03 South African Inventions Development Corp., Scientia, Pretoria,Transvaal Traegergebundenes immunogenes material
US4434150A (en) * 1981-10-19 1984-02-28 Ortho Diagnostic Systems, Inc. Immunological reagents employing polymeric backbone possessing reactive functional groups
US4644059A (en) * 1982-07-06 1987-02-17 Connaught Laboratories, Inc. Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US5126131A (en) * 1983-01-24 1992-06-30 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates.
US5370871A (en) * 1983-01-24 1994-12-06 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US4769237A (en) * 1983-03-25 1988-09-06 Bittle James L Synthetic picornavirus antigen
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4748111A (en) * 1984-03-12 1988-05-31 Molecular Diagnostics, Inc. Nucleic acid-protein conjugate used in immunoassay
US4666884A (en) * 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
US4863729A (en) * 1984-06-20 1989-09-05 Linus Pauling Institute Of Science And Medicine Method for preparing a macromolecular monoclonal antibody composition
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
US4824775A (en) * 1985-01-03 1989-04-25 Molecular Diagnostics, Inc. Cells labeled with multiple Fluorophores bound to a nucleic acid carrier
US4713240A (en) * 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
CA1239346A (en) * 1985-06-04 1988-07-19 Gursaran P. Talwar Birth control vaccine
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
AU1711888A (en) * 1987-04-24 1988-12-02 Biogen, Inc. Immunotherapeutic methods and compositions
GB8727489D0 (en) * 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
AU5649290A (en) * 1989-04-12 1990-11-05 New York University Dendritic polymer of multiple antigen peptide system useful as anti-malarial vaccine
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2098281A1 (en) * 1990-12-17 1992-06-18 Howard M. Dintzis Suppression of immune responses of oligomeric forms of antigen of controlled chemistry

Also Published As

Publication number Publication date
EP1958646A1 (en) 2008-08-20
ATE245446T1 (de) 2003-08-15
WO1993015760A1 (en) 1993-08-19
CA2129899A1 (en) 1993-08-12
NZ249704A (en) 1996-11-26
JPH07506811A (ja) 1995-07-27
US5955079A (en) 1999-09-21
AU3722093A (en) 1993-09-03
IL104696A (en) 1999-01-26
EP0625910A1 (en) 1994-11-30
EP0625910A4 (en) 1996-03-06
EP0911036A2 (en) 1999-04-28
CA2129899C (en) 2011-01-04
AU685047B2 (en) 1998-01-15
EP0625910B1 (en) 2003-07-23
ES2204900T3 (es) 2004-05-01
ZA93945B (en) 1994-10-31
US5585100A (en) 1996-12-17
JP3917172B2 (ja) 2007-05-23
EP0911036A3 (en) 2001-05-09
IL104696A0 (en) 1993-06-10
DE69333107D1 (de) 2003-08-28
DE69333107T2 (de) 2004-01-29

Similar Documents

Publication Publication Date Title
KR950700081A (ko) 이중 캐리어 면역원성 구성물
US5194254A (en) Enhancement of antigen immunogenicity
EP0245078B1 (en) Enhancement of antigen immunogenicity
CA1340956C (en) Synthetic peptides representing a t-cell epitope as a carrier molecule for conjugate vaccines
Alexander et al. Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses
Schneerson et al. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates.
US5573916A (en) Immunogenic constructs comprising b-cell and t-cell epitopes on common carrier
AU2005316864B2 (en) Glycoconjugate vaccines containing peptidoglycan
Barrios et al. Mycobacterial heat‐shock proteins as carrier molecules. II: The use of the 70‐kDa mycobacterial heat‐shock protein as carrier for conjugated vaccinescan circumvent the need for adjuvants and Bacillus Calmette Guérin priming
US5785973A (en) Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
US8591910B2 (en) Chemically programmable immunity
US7166708B2 (en) Process for preparing conjugate vaccines and the conjugate vaccines
JPH01501064A (ja) ワクチンとその製法
Jennings Further approaches for optimizing polysaccharide-protein conjugate vaccines for prevention of invasive bacterial disease
Rauly et al. Carrier properties of a protein derived from outer membrane protein A of Klebsiella pneumoniae
US6165468A (en) Antigenic carbohydrate linked to an immunogenic carrier
Coughlin et al. Adjuvant activity of QS-21 for experimental E. coli 018 polysaccharide vaccines
Malcolm et al. Surface layers from Bacillus alvei as a carrier for a Streptococcus pneumoniae conjugate vaccine
US5173293A (en) Anti-T-cell antibodies as adjuvants
CA1327523C (en) Antigen immunogenicity
Fattom Qualitative and quantitative immune response to bacterial capsular polysaccharides and their conjugates in mouse and man
SVENSON et al. Protection against Mouse Typhoid by Artificial Sa/mone//a Vaccines
WO1996039182A1 (en) Dual carrier immunogenic construct

Legal Events

Date Code Title Description
N231 Notification of change of applicant
N231 Notification of change of applicant
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application